Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;149(6):1958-1959.
doi: 10.1016/j.jaci.2022.03.026. Epub 2022 Apr 22.

The arrival of SARS-CoV-2-neutralizing antibodies in a currently available commercial immunoglobulin

Aaron L Miller  1 , Nicholas L Rider  2 , Richard B Pyles  3 , Barbara Judy  4 , Xuping Xie  5 , Pei-Yong Shi  5 , Thomas G Ksiazek  4
Affiliations

The arrival of SARS-CoV-2-neutralizing antibodies in a currently available commercial immunoglobulin

Aaron L Miller et al. J Allergy Clin Immunol. 2022 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
SARS-CoV-2 antibody assessment of Hizentra lots. A, Ten temporal lots of Hizentra were diluted for detection within the linear range of a SARS-CoV-2–specific ELISA. Lot 1 (expiration date December 14, 2022) is the leftmost sample, and lot 10 (expiration date December 22, 2023) is the rightmost sample, followed by the positive control (de-identified SARS-CoV-2 convalescent patient serum). The results for the 1:1600 dilution are depicted, indicating relative antibody levels (OD405 nm) at lot expiration dates. The threshold for ELISA positivity is shown as a dashed line (OD405 nm ≥ 0.2) established by a 1:400 dilution (not shown). B, All 10 sample lots (lots 6 through 10 are shown) were measured for neutralizing activities against SARS-CoV-2 engineered with an mNeonGreen (mNG) fluorescent reporter virus on VeroE6 cells by fluorescent focus reduction NT (FFRNT) as described previously., Error bars indicate SDs from duplicates. The nonlinear regression curves of the relative infectivity versus the Hizentra dilutions (log10 values) were created with Prism 9 (GraphPad Software, San Diego, Calif) and used to determine the fold dilution that neutralized 50% of mNG SARS-CoV-2 infectivity (defined as FFRNT50). The calculated NT50 values are shown for sample lots 6 to 10 (expiration dates Aug 8 through December 22, 2023).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Meyts I., Bucciol G., Quinti I., Neven B., Fischer A., Seoane E., et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147:520–531. - PMC - PubMed
    1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966. - PubMed
    1. Muruato A.E., Fontes-Garfias C.R., Ren P., Garcia-Blanco M.A., Menachery V.D., Xie X., et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11:4059. - PMC - PubMed
    1. Zou J., Xia H., Xie X., Kurhade C., Machado R.R.G., Weaver S.C., et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat Commun. 2022;13:852. - PMC - PubMed
    1. Stinca S., Barnes T.W., Vogel P., Meyers W., Schulte-Pelkum J., Filchtinski D., et al. Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches. PLoS One. 2021;16 - PMC - PubMed

Publication types